D.E. Shaw & Co
ASND icon

D.E. Shaw & Co’s Ascendis Pharma A/S ASND Stock Holding History

D.E. Shaw & Co’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,000
Closed -$1.27M – 5379
2021
Q3 		$1.27M Hold
8,000
– – ﹤0.01% 3407
2021
Q2 		$1.05M Hold
8,000
– – ﹤0.01% 3489
2021
Q1 		$1.03M Buy
+8,000
New +$1.22M ﹤0.01% 3083

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's ASND Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Ascendis Pharma A/S (ASND) stake by 99% in Q1 2026, selling an estimated $28M and leaving 1,062 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #4143.

D.E. Shaw & Co first reported a position in ASND in Q1 2018 and has held it in 33 quarters since. The position peaked at $51.4M in Q1 2024. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • D.E. Shaw & Co held 1,062 shares of Ascendis Pharma A/S worth $243K as of Q1 2026.
  • D.E. Shaw & Co sold 124,706 Ascendis Pharma A/S shares in Q1 2026, an estimated $28M.
  • Ascendis Pharma A/S made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4143 holding.
  • D.E. Shaw & Co first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 33 quarters since.
  • D.E. Shaw & Co's Ascendis Pharma A/S position peaked at $51.4M in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.